Consumers take the offensive against J&J for Tylenol recalls

A constant supply of bad news is jeopardizing the long-term sales of Tylenol and other Johnson & Johnson (NYSE: JNJ) products, says Motley Fool columnist Brian Orelli. "Contrary to the popular saying, there is such a thing as bad press and if you're getting it month after month, it's even worse." If J&J can't overcome the negative image quickly, he says, consumers will head to competing brand-name drugs or just grab generics. They also make take more direct action: Consumers are accusing the drugmaker of fraud and racketeering in a lawsuit stemming from the recent recall, and demanding cash refunds rather than replacement coupons. Column | Article

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.